AstraZeneca’s Fasenra meets primary endpoint in MANDARA Phase 3 trial for EGPA
AstraZeneca’s Fasenra met its primary endpoint in the MANDARA Phase III trial, offering a monthly treatment option for eosinophilic granulomatosis with polyangiitis (EGPA) patients. Fasenra demonstrated non-inferior remission rates compared to the thrice-a-month injections of mepolizumab, which is currently the only approved EGPA treatment. Fasenra vs. Mepolizumab: A Close Comparison in EGPA Treatment The MANDARA […]